DOCSLIB.ORG

The Reproducibility Crisis in Preclinical Research – Lessons to Learn from Clinical Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Reproducibility Crisis in Preclinical Research – Lessons to Learn from Clinical Research The reproducibility crisis in preclinical research – lessons to learn from clinical research Laia Pedro-Roig 1 and crisis. 1 The published literature is a common promotion, or tenure). Journal editors, referees, Christoph H. Emmerich 2 source for potential new drug targets used by the and grant reviewers look for the perfect story: 1 Trilogy Writing & Consulting GmbH, pharmaceutical industry, and publication results simple, clear, and complete. 3 These demands Frankfurt am Main, Germany are routinely validated in-house to ensure tempt investigators to cherry pick experiments 2 PAASP GmbH, Heidelberg, Germany reproducibility. According to Prinz et al., almost for publishing, develop hypotheses to fit the data, two-thirds of the validation projects conducted or keep collecting data until the desired at Bayer from 2007 to 2010 showed significance level is reached (p-hacking). Correspondence to: inconsistencies in results (including some from Competition among laboratories and pressure to Laia Pedro-Roig prestigious journals). 2 Begley and Ellis reported publish among scientists may result in negligent Trilogy Writing & Consulting GmbH that researchers at Amgen could only confirm the controlling or reporting of experimental Falkensteiner Strasse 77 scientific findings of six out of 53 (11%) conditions. 2 Another issue is the bias towards 60322 Frankfurt am Main, Germany landmark studies. 3 In addition, more than 70% of publishing positive results and the difficulties in [email protected] the researchers who participated in the Nature publishing results that contradict data in high- +49 69 138 2528-44 survey have failed to reproduce another scientist’s impact journals or currently established opinion results, and more than 50% admitted to having (publication bias). 2 This leads to strengthening Christoph Emmerich failed to reproduce their own. 1 certain hypotheses, even if there is a body of PAASP GmbH The reproducibility crisis is a quantifiable unpublished evidence against them. Am Aukopf 14-1 economic problem. Venture capital firms Published preclinical research often lacks 69118 Heidelberg, Germany consider that, when repeated by an independent proper quality standards in study [email protected] laboratory, the experiments in at least 50% of design (e.g., blinding and Low +49 696 777 8485 published studies do not provide the same randomisation) and valida - quality results. 4 In the US alone, US $28 billion per year tion of research tools that standards are spent on preclinical research that is not ensure the data obtained can make drug Abstract reproducible. 5 More importantly, the lack of is meaningful and un - candidates In recent years, the robustness and reproducibility has a negative impact on the biased. Begley and Ellis look more reproducibility of preclinical data have been bench-to-bedside time for new medicines, observed that authors of promising a topic for discussion. Quality standards and and increases drug development costs, as each reproducible preclinical than they good practices are often not well defined for study replication conducted by the pharma - cancer studies had paid actually different in vitro methods and in vivo models, ceutical industry to validate academic research close attention to controls, are. and not harmonised amongst preclinical findings requires 3 to 24 months of work and reagents, and description of the research laboratories. This results in poorly US $500,000 to $2 million. 5 complete dataset, while in studies that could not reliable literature, has a negative impact on the Data robustness becomes even more be reproduced, data were not routinely analysed bench-to-bedside time for new drugs, and important at later stages of preclinical research, by blinded investigators and often results from increases the resources needed for clinical when results determine “go/no-go” decisions for only one experiment were pre sent ed. 3 Accord - development. Clinical research, on the other drug candidates to enter clinical testing. A meta- ing to Freedman et al., errors leading to irrepro - hand, is tightly regulated and has high quality analysis identified higher effect sizes in animal ducibility of preclinical data can be due to study standards in place. Although improvements models of stroke in studies with low quality design, biological reagents and reference are slowly introduced, preclinical develop - standards. 6 This implies how low quality research materials, laboratory protocols, and data analysis ment (especially in its confirmatory phases) standards can make drug candidates look more and reporting. 5 would benefit from taking a closer look and promising than they actually are. An enduring challenge in drug development adapting more of the internationally accepted is the erroneous use and misinterpretation of principles used in clinical research. What is behind the preclinical data from cell lines and animal reproducibility crisis? models. In vitro cell culture systems are crucial Participants in the Nature survey consider that research tools for analysing complex mechanisms Reproducibility issues are gaining awareness the main reasons are pressure to publish and regulating cell biology. However, over 480 amongst preclinical scientists: in a Nature survey, selective reporting. 1 For academics, publishing is misidentified cell lines (as of November 2017) 52% of researchers state that there is a significant a career essential (e.g., for research funding, job routinely used in published studies are 28 | December 2017 Medical Writing | Volume 26 Number 4 Pedro-Roig and Emmerich – The reproducibility crisis in preclinical research the existing GxP standards (Good Laboratory Practice [GLP], Good Clinical Practice [GCP], Good Manufacturing Practice [GMP], etc.) can be used to ensure high quality preclinical research outcomes. Whether conducted in an academic or industrial laboratory, this non-regulated research is, however, essential to identify and validate novel drug targets and to build the basis for successful translation of preclinical data into clinically meaningful efficacy. Thus, there is a need for new specialised Good Research Practice (GRP) guidelines that focus on study design, unbiased conduct, statistical analysis, and transparent reporting. Clinical research, on the other hand, is highly regulated and adherence to quality standards is routinely monitored. Human experimentation has strong ethical restrictions that require researchers to comply with higher research standards to avoid submitting study participants to unnecessary risks. There are several lessons that preclinical research could learn from clinical research regarding quality standards. Lessons to learn from clinical research Clinical research is not perfect: A recent analysis of more than 5,000 papers in eight leading medical journals showed that roughly 2% of randomised controlled clinical trials may include fabricated data or lack adequate ethical app - roval. 13 However, clinical research is supported by strong standards and well-established proce - dures, as the following examples demonstrate, which could be used in preclinical research. contaminated, very frequently with HeLa cells identified as candidates for therapy in an ALS (list available from the International Cell Line mouse model. 8 Most of these compounds failed Declaration of Helsinki Authentication Committee [ICLAC]). 7 to slow the disease in animals (including eight As the cornerstone document of clinical research The causes behind the reproducibility crisis drugs that had previously looked promising, ethics , the Declaration of Helsinki helps ensure are not limited to a specific field (in vitro or in proceeded to clinical trials, and ultimately failed). that the risk to trial subjects is proportionate to vivo) of preclinical research or therapeutic area. These discrepancies are likely due to the low the benefit expected to society. Similar codes of The limitations of preclinical cancer models quality standards of the original publications, as practice would help preclinical researchers to include (i) the use of a small number of poorly most did not include statistical models to realise that there is an implicit responsibility in characterised tumour cell lines that inadequately minimise experimental noise or implement all their activities. Currently, a similar concept recapitulate human disease, (ii) the inability to blinding and randomisation procedures. exists only for animal research: the 3Rs capture the human tumour environment, (iii) the (Replacement, Reduction, and Refinement) are lack of consideration for pharmacodynamics and What is the current situation considered in the US Guide for the Care and Use pharmacokinetics, (iv) the use of problematic and what could be done? of Laboratory Animals and the European endpoints and testing strategies, and (v) the There are no commonly accepted and followed Directive 2010/63/EU. 14,15 These guidelines regular exclusion of predictive biomarkers guidelines and quality standards for encourage finding alternatives to the use of for efficacy. 3 In the amyotrophic lateral The preclinical research outside those animals, using the right number of animals, sclerosis (ALS) field, Steve Perrin reproducibility intended for studies that directly refining breeding, accommodation and care, and and his team re-examined 100 crisis is a quantifiable support drug marketing autho - minimising distress. Of note, “reduction” means compounds that had been economic problem. risations. 9-12 Indeed, none
Load more

Recommended publications
  • Medical Writing Services 1 Medical Writing Services Experts Guiding You Through Your Journey
    PAREXEL® CLINICAL RESEARCH SERVICES MEDICAL WRITING SERVICES 1 MEDICAL WRITING SERVICES EXPERTS GUIDING YOU THROUGH YOUR JOURNEY PAREXEL’s Medical Writing Services team is one of the largest and most experienced in the biopharmaceutical industry, providing a wide range of high-quality documents from Phase I through to post-marketing and beyond. We can offer medical writing services for standalone projects, functional service partnerships or as a fully integrated service within our clinical research programs. MEDICAL WRITING PROJECTS COMPLETED: 2300 by PAREXEL’s Medical Writing Services team from 2009 to 2014 2 PAREXEL MEDICAL WRITING SERVICES ICF PRODUCES HIGH QUALITY DOCUMENTS ACROSS THE PRODUCT DSUR, Protocol IB LIFE CYCLE IND AR The Medical Writing Services group at PAREXEL is uniquely qualified to help you compile, organize, write, edit, and produce a wide range of medical and scientific documentation required to support your product Key: development efforts. We offer fast turnaround and a ICF = Inform Consent Form flexible, efficient process for any project large or small. IB = Investigator Brochure DSUR = Development Safety Update Reports IND AR = Investigational New Drug Annual Reports CSR = Clinical Study Report CTRS = Clinical Trial Result Summary PBRER = Periodic Benefit-Risk Evaluation Report PSUR = Periodic Safety Update Report PADER = Periodic Adverse Drug Experience Report CTD = Common Technical Document NDA = New Drug Application 3 Taking a new medicine or medical device from concept PAREXEL’s Medical Writing Services department to market requires writing and submitting hundreds of includes a large number of scientists with significant thousands of pages of documentation. To minimize time expertise in the therapeutic areas that are important to market, these documents and reports must be to you.
    [Show full text]
  • Reproducibility, Replicability, and Generalization in the Social, Behavioral, and Economic Sciences
    REPRODUCIBILITY, REPLICABILITY, AND GENERALIZATION IN THE SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES Report of the Subcommittee on Replicability in Science of the SBE Advisory Committee to the National Science Foundation 13 May 2015 Presentation at SBE AC Spring Meeting by K. Bollen. Report of the Subcommittee on Replicability in Science Advisory Committee to the NSF SBE Directorate Subcommittee Members: Kenneth Bollen (University of North Carolina at Chapel Hill, Cochair) John T. Cacioppo (University of Chicago, Cochair) Robert M. Kaplan (Agency for Healthcare Research and Quality) Jon A. Krosnick (Stanford University) James L. Olds (George Mason University) Staff Assistance Heather Dean (National Science Foundation) TOPICS I. Background II. Subcommittee Report III. Definitions IV. Recommendations V. Final Comments Background • Spring, 2013 o NSF SBE Advisory Committee establishes subcommittee on how SBE can promote robust research practices • Summer & Fall 2013 o Subcommittee proposal for workshop on “Robust Research in the Social, Behavioral, and Economic Sciences.” • February 20-21, 2014 o Workshop convened o Participants drawn from variety of universities, funding agencies, scientific associations, and journals o Cover broad range of issues from extent and cause of problems to possible solutions o Details are in the appendix of the circulated report • Post-workshop period o Document & digest workshop content o Discuss and propose recommendations o Complete report Subcommittee Report • DEFINITIONS o No consensus in science on the meanings
    [Show full text]
  • Meta Analyses – Pros and Cons
    Meta analyses – pros and cons Emily S Sena, PhD Centre for Clinical Brain Sciences, University of Edinburgh @camarades_ CAMARADES: Bringing evidence to translational medicine CAMARADES • Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies • Look systematically across the modelling of a range of conditions • Data Repository – 30 Diseases – 40 Projects – 25,000 studies – from over 400,000 animals CAMARADES: Bringing evidence to translational medicine Why do we do meta-analysis of animal studies? • Animal models are generally performed to inform human health but when should you be convinced to move to the next step? • Systematic reviews & meta-analyses: – assess the quality and range of evidence – identify gaps in the field – quantify relative utility of outcome measures – inform power/sample size calculations – assess for publication bias – try to explain discrepancies between preclinical and clinical trial results – inform clinical trial design CAMARADES: Bringing evidence to translational medicine Systematic review and meta-analysis • Pros – What have we learnt about…….. • Translation? • Quality? • The 3Rs? • Cons – What are the limitations? • As good as the data that goes in? • Rapidly outdated • The Impact CAMARADES: Bringing evidence to translational medicine Systematic review and meta-analysis • Pros – What have we learnt about…….. • Translation? • Quality? • The 3Rs? • Cons – What are the limitations? • As good as the data that goes in? • Rapidly outdated • The Impact CAMARADES: Bringing evidence
    [Show full text]
  • Professional Medical Writing Support and the Quality of Randomised Controlled Trial Reporting: a Cross-Sectional Study
    Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study William Gattrell, Sally Hopewell, Kate Young, Paul Farrow, Richard White, Elizabeth Wager and Christopher Winchester MedComms Networking Event 4 May 2016 Paul Farrow DPhil CMPP ! Communications Director at Oxford PharmaGenesis −" More than 10 years of experience in medical communications −" Contract Global Publications Lead for a top-10 pharma company −" Head of the PharmaGenesis Publications Ethics, Planning and Research group −" GPP3 reviewer −" Guest lecturer on GPP at the University of Oxford, UK 2 Medical writing is misunderstood and sometimes gets bad press 3 Our industry bodies say … “Involving medical writers may therefore raise the standard of publications and accelerate the writing and publication process”1 “... medical writers can often improve the efficiency and effectiveness of manuscript preparation by working with the research team to develop clear and concise manuscripts in a timely fashion”2 … but is there any evidence to support these statements? 1. Jacobs A, Wager E. Curr Med Res Opin 2005;21:317–22; 2. Norris R et al. Curr Med Res Opin 2007;23:1837–40 4 Available evidence “When professional medical writers help authors prepare manuscripts, these manuscripts are less likely to be retracted for misconduct,22 are more compliant with best-practice reporting guidelines,23 and are accepted more quickly for publication24” Woolley KL et al. Poor compliance with reporting research results – we know it’s a problem … how do we fix it? Curr Med Res Opin 2012;28:1857–60 22. Woolley KL et al. Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study.
    [Show full text]
  • Medical Writing June 2019, Volume 28 Number 2
    Biosimilar development – an overview Diana Radovan Trilogy Writing and Consulting GmbH, Frankfurt am Main, Germany Correspondence to: Diana Radovan Senior Medical Writer Trilogy Writing and Consulting GmbH, Falkensteiner Str. 77, 60322 Frankfurt am Main, Germany +49 69 138 2528 56 [email protected] Abstract Biosimilars are biological drugs that are similar to, and cheaper than other biological drugs (called “reference originator biologics”) that are already in use. They share an identical amino-acid sequence but, given the inherent variability of biological molecules, not full Since biologics and “sameness”. Biosimilar registration follows a biosimilars are created in strictly regulated pathway based on a totality- of-evidence approach. This article critically living cells, they cannot discusses the particulars of biosimilar devel - be chemically synthesised opment, including the continuous develop - like generic drugs. ment of regulatory guidelines, familiarises readers with biosimilar-specific terminology, addresses the typical challenges of writing biosimilar dossiers, and summarises future directions in biosimilar development in the and biosimilars are created in living cells, they biological medicine already approved in the EU, context of a changing competitive landscape. cannot be chemically synthesised like for which there are no clinically meaningful After reading this article, medical writers with conventional drugs and their generics. differences to the reference medicine in terms of different backgrounds, including those While a biosimilar candidate and an safety, quality and efficacy. 2 In the US, a previously unfamiliar with key aspects of originator biologic share the same amino-acid biosimilar product is defined as a biologic biosimilar development, should be able to sequence, they can never be identical, due to the product approved based on demonstrating that better understand and apply these guidelines inherent variability of complex biological it is highly similar to an US FDA-approved in their daily biosimilar work.
    [Show full text]
  • Medical Writing Management Vol
    Vol.Vol. 18, 20, No. No. 2, 4, 2009, 2011, ISSNISSN 1854-8466.1854-8466. Medical writing management Vol. 20, No. 4, 2011 The Write Stuff EMWA Executive Committee Journal insights The Write Stuff is the offi cial publication of the European Medical Writers Asso- ciation. It is issued 4 times a year and aims to provide EMWA members with relevant, President: informative and interesting articles and news addressing issues relating to the broad Rita Wellens arena of medical writing. We are open to contributions from anyone whose ideas can Wellens Clinical Research Consulting complement these aims, but opinions expressed in individual articles are those of the Rillaar, Belgium authors and are not necessarily those held by EMWA as an association. Articles or ideas should be submitted to the Journal Editor (see below) or another [email protected] member of the Editorial Board. Vice President: Subscriptions Please contact Maney Publishing’s Customer Services & Subscriptions Team at sub- Susan Batti [email protected] for subscription information or view http://www.maney. Premier Research Germany Ltd., co.uk/journals/mew. Darmstadt, Germany, [email protected] Instructions for contributors • The Write Stuff typically publishes articles of 800–2500 words although long- er pieces or those with tables or graphics will be considered. Treasurer: • All articles are subject to editing and revision by the Editorial Board. Any chang- Gillian Pritchard es will be discussed with the author before publication. Sylexis Limited • Submissions should include the full address of the author, including the telephone Dundee, UK and fax numbers and e-mail address. Suitable quotes for side boxes can be indi- [email protected] cated or they can be selected by the Editorial Board.
    [Show full text]
  • Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification
    in vivo 28: 1005-1012 (2014) Review Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification MARCO RASTRELLI1, SAVERIA TROPEA1, CARLO RICCARDO ROSSI2 and MAURO ALAIBAC3 1Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV- IRCCS, Padova, Italy; 2Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS and Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; 3Dermatology Unit, University of Padova, Padova, Italy Abstract. This article reviews epidemiology, risk factors, Epidemiology pathogenesis and diagnosis of melanoma. Data on melanoma from the majority of countries show a rapid At the start of 21st century, melanoma remains a potentially increase of the incidence of this cancer, with a slowing of fatal malignancy. At a time when the incidence of many the rate of incidence in the period 1990-2000. Males are tumor types is decreasing, melanoma incidence continues to approximately 1.5-times more likely to develop melanoma increase (1). Although most patients have localized disease than females, while according to other studies, the different at the time of the diagnosis and are treated by surgical prevalence in both sexes must be analyzed in relation with excision of the primary tumor, many patients develop age: the incidence rate of melanoma is grater in women metastases (2). than men until they reach the age of 40 years, however, by The incidence of malignant melanoma has been increasing 75 years of age, the incidence is almost 3-times as high in worldwide, resulting in an important socio-economic men versus women. The most important and potentially problem. From being a rare cancer one century ago, the modifiable environmental risk factor for developing average lifetime risk for melanoma has now reached 1 in 50 malignant melanoma is the exposure to ultraviolet (UV) in many Western populations (3).
    [Show full text]
  • Certification Accredited Schools List
    = Academic Clinical Research Programs Which Currently Meet Waiver Requirements for the Academy of Clinical Research Professional (Updated October 15, 2015) This list includes academic clinical research programs which, as of the above date, have been evaluated and found to meet the current waiver requirements established by the Academy of Clinical Research Professionals (Academy) Board of Trustees. Programs that meet the waiver requirements allow a candidate to waive 1,500 hours of hands-on experience performing the Essential Duties of the program to which the candidate has made application. This list is not to be considered exhaustive and is not designed to represent all the academic offerings available. Appearance on this list is not to be construed as an endorsement of its content or format by the Academy or a guarantee that a candidate will be eligible for certification. All individuals interested in enrolling in a program of study should evaluate any program on the basis of his or her personal needs. (* - programs marked with an asterisk MAY be accepted but acceptance will be dependent on the complete listing of courses completed) Individuals seeking additional information about each program should contact the institution directly. Academic Institution Program Name ( Click Title for Web Navigation) Academy of Applied Pharmaceutical Sciences Clinical Research Diploma Program American University of Health Sciences Master of Science in Clinical Research Anoka-Ramsey Community College Clinical Research Professional - Certificate Graduate
    [Show full text]
  • Adaptive Enrichment Designs in Clinical Trials
    Annual Review of Statistics and Its Application Adaptive Enrichment Designs in Clinical Trials Peter F. Thall Department of Biostatistics, M.D. Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA; email: [email protected] Annu. Rev. Stat. Appl. 2021. 8:393–411 Keywords The Annual Review of Statistics and Its Application is adaptive signature design, Bayesian design, biomarker, clinical trial, group online at statistics.annualreviews.org sequential design, precision medicine, subset selection, targeted therapy, https://doi.org/10.1146/annurev-statistics-040720- variable selection 032818 Copyright © 2021 by Annual Reviews. Abstract All rights reserved Adaptive enrichment designs for clinical trials may include rules that use in- terim data to identify treatment-sensitive patient subgroups, select or com- pare treatments, or change entry criteria. A common setting is a trial to Annu. Rev. Stat. Appl. 2021.8:393-411. Downloaded from www.annualreviews.org compare a new biologically targeted agent to standard therapy. An enrich- ment design’s structure depends on its goals, how it accounts for patient heterogeneity and treatment effects, and practical constraints. This article Access provided by University of Texas - M.D. Anderson Cancer Center on 03/10/21. For personal use only. first covers basic concepts, including treatment-biomarker interaction, pre- cision medicine, selection bias, and sequentially adaptive decision making, and briefly describes some different types of enrichment. Numerical illus- trations are provided for qualitatively different cases involving treatment- biomarker interactions. Reviews are given of adaptive signature designs; a Bayesian design that uses a random partition to identify treatment-sensitive biomarker subgroups and assign treatments; and designs that enrich superior treatment sample sizes overall or within subgroups, make subgroup-specific decisions, or include outcome-adaptive randomization.
    [Show full text]
  • Placebo-Controlled Trials of New Drugs: Ethical Considerations
    Reviews/Commentaries/Position Statements COMMENTARY Placebo-Controlled Trials of New Drugs: Ethical Considerations DAVID ORENTLICHER, MD, JD als, placebo controls are not appropriate when patients’ health would be placed at significant risk (8–10). A placebo- controlled study for a new hair- uch controversy exists regarding sufficiently more effective than placebo to thickening agent could be justified; a the ethics of placebo-controlled justify its use. Finally, not all established placebo-controlled study for patients M trials in which an experimental therapies have been shown to be superior with moderate or severe hypertension therapy will compete with an already es- to placebo. If newer drugs are compared would not be acceptable (11). Similarly, if tablished treatment (or treatments). In with the unproven existing therapies, an illness causes problems when it goes such cases, argue critics, patients in the then patients may continue to receive untreated for a long period of time, a 52- control arm of the study should receive an drugs that are harmful without being week study with a placebo control is accepted therapy rather than a placebo. helpful. much more difficult to justify than a By using an active and effective drug, the Moreover, say proponents of placebo 6-week study (12). control patients would not be placed at controls, patients can be protected from When David S.H. Bell (13) explains risk for deterioration of their disease, and harm by “escape” criteria, which call for why placebo controls are unacceptable the study would generate more meaning- withdrawal from the trial if the patient for new drugs to treat type 2 diabetes, he ful results for physicians.
    [Show full text]
  • Generating Real-World Evidence by Strengthening Real-World Data Sources
    Generating Real-World Evidence by Strengthening Real-World Data Sources Using “real-world evidence” to bring new “Every day, health care professionals are updating patients’ treatments to patients as part of the 21st electronic health records with data on clinical outcomes Century Cures Act (the “Cures Act”) is a key resulting from medical interventions used in routine clinical priority for the Department of Health and practice. As our experience with new medical products Human Services (HHS). Specifically, the Cures expands, our knowledge about how to best maximize their Act places focus on the use of real-world data benefits and minimize potential risks sharpens with each data to support regulatory decision-making, including point we gather. Every clinical use of a product produces data the approval of new indications for existing that can help better inform us about its safety and efficacy.” drugs in order to make drug development faster jacqueline corrigan-curay, md, jd and more efficient. As such, the Cures Act director of the office of medical policy in fda’s center for drug evaluation and research has tasked the Food and Drug Administration (FDA) to develop a framework and guidance for evaluating real-world evidence in the context of drug regulation.1 Under the FDA’s framework, real-world evidence (RWE) is generated by different study designs or analyses, including but not limited to, randomized trials like large simple trials, pragmatic trials, and observational studies. RWE is the clinical evidence about the use, potential benefits, and potential risks of a medical product based on an analysis of real-world data (RWD).
    [Show full text]
  • The 5 Levels of Evidence in Evidence-Based Medicine
    evidence-based medicine the 5 levels of evidence in evidence-based medicine DISCLAIMER This material is provided for informational purposes only. The material does not constitute legal or professional advice nor does it necessarily represent the position of the Tech Observer Group. In case of doubts relating to this material, please consult your company's internal policy on scientific publications. hello there! Ever thought that scientific publications are too complex? Or that publishing your research seems too daunting a task? To make things easier, we have developed a series of bite-sized guides covering a range of topics on scientific publications. Let's make the complex simple. tech Observer medical communications EVIDENCE-BASED MEDICINE Strongest More and more healthcare professionals are consulting Evidence the literature and gathering research evidence to inform their clinical decisions. However, not all published evidence are equally convincing. Meta- analysis Level 1 The evidence pyramid to the left presents a hierarchy systematic of study types. The higher up the pyramid, the review more rigorous the study methodology and randomized trial hence the more likely it is that the study design can minimize the effect of 2 cohort study bias on the study results. 3 case-control study Here is a quick overview of the 5 levels 4 Case series/report of evidence in evidence-based 5 Weakest medicine. expert opinion Evidence 55levels of evidence in evidence-based medicine level 1 High quality randomized controlled trials and systematic reviews and meta- analyses of randomized controlled trials level 2 Cohort studies and systematic reviews of cohort studies level 3 Case-control studies and systematic reviews of case-control studies level 4 Case series and case reports level 5 Expert opinion and narrative reviews Strongest Evidence WRAPPING UP The evidence-based Meta- medicine movement has given analysis Level 1 publications of research an systematic review increasingly influential role in clinical practice.
    [Show full text]